This article is more than 5 years old. Information may no longer be current.

Patients with metastatic melanoma improved progression-free survival with Abraxane

Chemotherapy-naive patients with metastatic melanoma who received Abraxane demonstrated significant improvement in progression-free survival compared with patients receiving dacarbazine, according to a news release.

Data from the phase 3, randomized, international study of Abraxane (Celgene Corp.), paclitaxel protein-bound particles for injectible suspension (albumin-bound), is scheduled to be presented at the Society for Melanoma Research Congress in November in Los Angeles, a Swiss subsidiary of the company said Tuesday.

The Celgene-sponsored study (CA033) compared Abraxane with standard chemotherapy dacarbazine (DTIC) in patients with metastatic melanoma. The trial included 529 chemotherapy-naive patients randomly assigned to either 150 mg/m² Abraxane weekly for 3 out of 4 weeks or 1,000 mg/m² DTIC every three weeks, according to the release. Independently assessed progression-free survival was the primary endpoint. Overall survival, overall response rate and disease control, safety and tolerability were secondary endpoints.

Abraxane is currently approved for treatment of patients with breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, according to the release.